marijuana stock news

Form 8-K for AEROGROW INTERNATIONAL, INC.


10-Jul-2015

Entry into a Material Definitive Agreement, Creation of a Direct Fin

Item 1.01 Entry into a Material Definitive Agreement.On July 6, 2015, AeroGrow International, Inc. (the “Company”) entered a $6.0 Million Term Loan Agreement with The Scotts Miracle-Gro Company. The funding will provide general working capital to support anticipated growth as the Company expands its retail and its direct-to-consumer sales channels. The proceeds will be made available as needed in three advances of up to $2.0 million, $2.5 million, and $1.5 million in July, August, and September, respectively with a due date of April 15, 2016. Interest will be charged at the stated rate of 10%, but will paid in shares of AeroGrow common stock, valued at a price per share equal to the Series B Preferred Conversion Price on the date the Term Loan is paid in full.

As previously reported in a Current Report on Form 8-K filed with the SEC on April 23, 2013, the Company entered into a strategic alliance with The Scotts Miracle-Gro Company in which, among other things, the Company issued: (i) 2,649,007 shares of Series B Convertible Preferred Stock to a wholly owned subsidiary of Scotts Miracle-Gro; and (ii) a warrant to purchase shares of the Company’s common stock for an aggregate purchase price of $4.0 million. As reported in the Company’s Annual Report on Form 10-K for the year ended March 31, 2015, The Scotts Miracle-Gro Company and its affiliates beneficially own approximately 34.0% of the Company’s common stock (on an as-converted basis). The Term Loan was approved by disinterested members of the Company’s Board of Directors.

The foregoing description of the $6.0 Million Term Loan Agreement does not purport to be complete, and is qualified in its entirety by reference to the full text of the agreement, which is filed as Exhibit 10.1 hereto and are incorporated herein by reference.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.The information set forth in Item 1.01 above is incorporated herein by reference.

 

Item 3.02 Unregistered Sales of Equity SecuritiesTo the extent that the Company has agreed to issue common stock as interest on the $6.0 Million Term Loan Agreement, the information set forth in Item 1.01 above is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number                          Description

     10.1            Term Loan and Security Agreement
     99.1            Press Release Issued by AeroGrow International, Inc.
                   on July 9, 2015

Portions of this report and the press release filed as Exhibit 99.1 may constitute “forward-looking statements” as defined by federal law. Although the Company believes any such statements are based on reasonable assumptions, there is no assurance that actual outcomes will not be materially different. Any such statements are made in reliance on the “safe harbor” protections provided under the Private Securities Litigation Reform Act of 1995. Additional information about issues that could lead to material changes in the Company’s performance is contained in the Company’s filings with the Securities and Exchange Commission.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$STEV Provides Update on 10-K Filing

Stevia Corp. Provides Update on 10-K Filing  Stevia Corp. (OTC PINK: STEV)…

mCig, Inc. (MCIG) Shareholder Update – CEO Defines Direction of the Company

MCIG Shareholder Update – CEO Defines Direction of the Company mCig, Inc.…

Village Farms International (VFF) Acquires 100% of Balanced Health Botanicals

Village Farms International Acquires 100% of Balanced Health Botanicals, a Profitable Leader…

GT Biopharma (OXISD) Hires Former Pfizer CMO/Vice President and Senior Director of Oncology Research as CMO

LOS ANGELES, CA / ACCESSWIRE / September 7, 2017 / GT Biopharma…